CONTEXT: Preadipocyte factor 1 (pref-1) is increased in anorexia nervosa and is associated negatively with bone mineral density (BMD). No previous studies exist on pref-1 in women with exercise-induced hypothalamic amenorrhea (HA), which similar to anorexia nervosa, is an energy-deficiency state associated with hypoleptinemia. OBJECTIVE: Our objective was to evaluate whether pref-1 levels are also elevated and associated with low BMD and to assess whether leptin regulates pref-1 levels in women with HA. DESIGN: Study 1 was a double-blinded, placebo-controlled randomized clinical trial of metreleptin administration in women with HA. Study 2 was an open-label study of metreleptin administration in low physiological, supraphysiological, and pharmacological doses in healthy women volunteers. SETTING AND PATIENTS: At Beth Israel Deaconess Medical Center, 20 women with HA and leptin levels higher than 5 ng/ml and nine healthy control women participated in study 1, and five healthy women participated in study 2. INTERVENTION: For study 1, 20 HA subjects were randomized to receive either 0.08 mg/kg metreleptin (n = 11) or placebo (n = 9). For study 2, five healthy subjects received 0.01, 0.1, and 0.3 mg/kg metreleptin in both fed and fasting conditions for 1 and 3 d, respectively. MAIN OUTCOME MEASURES: Circulating pref-1 and leptin levels were measured. RESULTS: Pref-1 was significantly higher in HA subjects vs. controls (P = 0.035) and negatively associated with BMD (ρ = -0.38; P < 0.01) and bone mineral content (ρ = -0.32; P < 0.05). Metreleptin administration did not alter pref-1 levels in any study reported herein. CONCLUSIONS: Pref-1 is higher in HA subjects than controls. Metreleptin administration at low physiological, supraphysiological, and pharmacological doses does not affect pref-1 levels, suggesting that hypoleptinemia is not responsible for higher pref-1 levels and that leptin does not regulate pref-1.
RCT Entities:
CONTEXT: Preadipocyte factor 1 (pref-1) is increased in anorexia nervosa and is associated negatively with bone mineral density (BMD). No previous studies exist on pref-1 in women with exercise-induced hypothalamic amenorrhea (HA), which similar to anorexia nervosa, is an energy-deficiency state associated with hypoleptinemia. OBJECTIVE: Our objective was to evaluate whether pref-1 levels are also elevated and associated with low BMD and to assess whether leptin regulates pref-1 levels in women with HA. DESIGN: Study 1 was a double-blinded, placebo-controlled randomized clinical trial of metreleptin administration in women with HA. Study 2 was an open-label study of metreleptin administration in low physiological, supraphysiological, and pharmacological doses in healthy women volunteers. SETTING AND PATIENTS: At Beth Israel Deaconess Medical Center, 20 women with HA and leptin levels higher than 5 ng/ml and nine healthy control women participated in study 1, and five healthy women participated in study 2. INTERVENTION: For study 1, 20 HA subjects were randomized to receive either 0.08 mg/kg metreleptin (n = 11) or placebo (n = 9). For study 2, five healthy subjects received 0.01, 0.1, and 0.3 mg/kg metreleptin in both fed and fasting conditions for 1 and 3 d, respectively. MAIN OUTCOME MEASURES: Circulating pref-1 and leptin levels were measured. RESULTS:Pref-1 was significantly higher in HA subjects vs. controls (P = 0.035) and negatively associated with BMD (ρ = -0.38; P < 0.01) and bone mineral content (ρ = -0.32; P < 0.05). Metreleptin administration did not alter pref-1 levels in any study reported herein. CONCLUSIONS:Pref-1 is higher in HA subjects than controls. Metreleptin administration at low physiological, supraphysiological, and pharmacological doses does not affect pref-1 levels, suggesting that hypoleptinemia is not responsible for higher pref-1 levels and that leptin does not regulate pref-1.
Authors: Sharon H Chou; John P Chamberland; Xiaowen Liu; Giuseppe Matarese; Chuanyun Gao; Rianna Stefanakis; Mary T Brinkoetter; Huizhi Gong; Kalliopi Arampatzi; Christos S Mantzoros Journal: Proc Natl Acad Sci U S A Date: 2011-04-04 Impact factor: 11.205
Authors: James N Roemmich; Pamela A Clark; Christos S Mantzoros; Cathy M Gurgol; Art Weltman; Alan D Rogol Journal: J Clin Endocrinol Metab Date: 2003-02 Impact factor: 5.958
Authors: Corrine K Welt; Jean L Chan; John Bullen; Robyn Murphy; Patricia Smith; Alex M DePaoli; Aspasia Karalis; Christos S Mantzoros Journal: N Engl J Med Date: 2004-09-02 Impact factor: 91.245
Authors: I Sadaf Farooqi; Giuseppe Matarese; Graham M Lord; Julia M Keogh; Elizabeth Lawrence; Chizo Agwu; Veronica Sanna; Susan A Jebb; Francesco Perna; Silvia Fontana; Robert I Lechler; Alex M DePaoli; Stephen O'Rahilly Journal: J Clin Invest Date: 2002-10 Impact factor: 14.808
Authors: Christos S Mantzoros; Faidon Magkos; Mary Brinkoetter; Elizabeth Sienkiewicz; Tina A Dardeno; Sang-Yong Kim; Ole-Petter R Hamnvik; Anastasia Koniaris Journal: Am J Physiol Endocrinol Metab Date: 2011-07-26 Impact factor: 4.310
Authors: J Jürimäe; V Tillmann; A Cicchella; C Stefanelli; K Võsoberg; A L Tamm; T Jürimäe Journal: Osteoporos Int Date: 2015-09-01 Impact factor: 4.507
Authors: Francis de Zegher; Marta Díaz; Giorgia Sebastiani; Ana Martín-Ancel; David Sánchez-Infantes; Abel López-Bermejo; Lourdes Ibáñez Journal: Diabetes Care Date: 2012-02-14 Impact factor: 19.112